See the Complete Picture.
Published loading...Updated

FDA Crackdown on Off-Brand Ozempic Products Set to Take Effect, Threatening Supply and Access for Many

  • The FDA will enforce a federal deadline on May 22 to stop sales of compounded off-brand semaglutide drugs like Ozempic and Wegovy in the U.S.
  • This crackdown follows an end to drug shortages declared by the FDA in February and comes after increased demand since 2022 strained supplies.
  • Compounded versions, often cheaper and made by pharmacies without FDA approval, have been widely used but linked to about 1,000 adverse side effect reports by April 30.
  • Novo Nordisk, maker of Ozempic and Wegovy, intensified legal actions with nearly 120 lawsuits and offers a $300 discount on Wegovy through June 30 to encourage use of approved products.
  • Ending compounded drug sales may tighten overall supply and financial access for many patients reliant on these cheaper alternatives, while approved GLP-1 drugs remain fully available.
Insights by Ground AI
Does this summary seem wrong?

105 Articles

All
Left
11
Center
55
Right
8
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 74% of the sources are Center
74% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Grocery Gazette - Latest Grocery Industry News broke the news in on Monday, May 19, 2025.
Sources are mostly out of (0)